Dr. Ahmad Masri and Dr. C Michael Gibson discuss outpatient worsening heart failure in transthyretin amyloid cardiomyopathy in the Attribute-CM trial
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
.
Search
Dr. Eugene Brailovsky and Dr. C. Michael Gibson discuss: AF Outcomes and Cardiac Conduction Abnormalities In ATTRibute-CM
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
Dr. Steve Nissen and Dr. C. Michael Gibson discuss how management is evolving beyond statins alone—highlighting earlier combination therapy, lower LDL-C goals, and expanded roles for non-statin therapy
Sponsored by Esperion Therapeutics Inc., who did not influence the content of the presentation
Dr. Neha Pagidipati and Dr. C. Michael Gibson discuss how the new lipid guidelines are moving the needle on LDL lowering: earlier, lower, longer.
The recent Vesalius trial adds to the data supporting lower is better, and suggests that even lower (an achieved LDL of 45 […]
Dr. Prem Soman and Dr. C. Michael Gibson Discuss: Long-Term Survival Benefits and Disease Stabilization With Acoramidis In Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.